Prosecution Insights
Prosecution Insights
35 pending office actions • 22 art units • 33 examiners • 0 of 35 (0%) have an AI response strategy ready • 45 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 19 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 19 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (3%) |
| §103 only | 9 (26%) |
| §102 only | 3 (9%) |
| §112 only | 2 (6%) |
| Double-patenting only | 1 (3%) |
| Double-patenting + other | 4 (11%) |
| Multi-statute (no §101) | 14 (40%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 2 | 64.1% | +27.7% |
| REDDIG, PETER J | 2 | 58.1% | +39.9% |
| WARD, PAUL V | 1 | 83.1% | -11.9% |
| BURKHART, MICHAEL D | 1 | 62.2% | +11.5% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.0% | +16.2% |
| GIBBS, TERRA C | 1 | 63.9% | +10.4% |
| GANGLE, BRIAN J | 1 | 76.6% | +15.2% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.3% |
| WELLS, LAUREN QUINLAN | 1 | 46.6% | +61.8% |
| BERTOGLIO, VALARIE E | 1 | 63.9% | +30.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18842728 | PCNA INHIBITORS AND USES THEREOF | WARD, PAUL V | — |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032052 | VACCINATION OF HEMATOPOIETIC STEM CELL DONORS WITH CYTOMEGALOVIRUS TRIPLEX COMPOSITION | SALVOZA, M FRANCO G | 98d overdue |
| 17919178 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | REDDIG, PETER J | 8d overdue |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 12d |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | DROUIN, STEVE HOANG | 28d |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18023536 | NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF | LUNDE, GRACE HENRY | 34d |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 48d |
| 18033777 | ENGINEERED NK CELLS | HAM, JIEUN | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 28d overdue |
| 17789930 | METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS | BELYAVSKYI, MICHAIL A | 16d overdue |
| 17919178 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | REDDIG, PETER J | 8d overdue |
| 18488859 | TREATMENT OF CANAVAN DISEASE | BERTOGLIO, VALARIE E | 21d |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | BURKHART, MICHAEL D | — |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | KINSEY WHITE, NICOLE ERIN | — |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | GANGLE, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1644 | 3 |
| 1635 | 2 |
| 1645 | 2 |
| 1647 | 2 |
| 1643 | 2 |
| 1675 | 2 |
| 1626 | 1 |
| 1632 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842728 | PCNA INHIBITORS AND USES THEREOF | WARD, PAUL V | — | §112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | BURKHART, MICHAEL D | — | §102 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | KINSEY WHITE, NICOLE ERIN | — | §102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 1635 | §102§103 | Non-Final OA | 29d | Pending | May 02, 2024 |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | GANGLE, BRIAN J | 1645 | §102 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | LANDSMAN, ROBERT S | — | §103 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18288692 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | 1626 | §103DP | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18488859 | TREATMENT OF CANAVAN DISEASE | BERTOGLIO, VALARIE E | 1632 | Other | Final Rejection | 21d | Pending | Oct 17, 2023 |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | MEYERING, SHABANA SHABBEER | 1635 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18548677 | T-CELLS FOR ANTI-HIV CAR-T THERAPY AND METHODS OF USE | CHASE, CAROL ANN | 1646 | §103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 28d overdue | Pending | Aug 15, 2023 |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | DROUIN, STEVE HOANG | 1627 | §102§103§112 | Non-Final OA | 28d | Pending | Jul 28, 2023 |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 1647 | §101§102§103§112 | Non-Final OA | 48d | Pending | Jul 05, 2023 |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 1633 | §102§103 | Non-Final OA | 12d | Pending | Jun 06, 2023 |
| 18033777 | ENGINEERED NK CELLS | HAM, JIEUN | 1643 | §102§103Other | Non-Final OA | 56d | Pending | Apr 25, 2023 |
| 18032052 | VACCINATION OF HEMATOPOIETIC STEM CELL DONORS WITH CYTOMEGALOVIRUS TRIPLEX COMPOSITION | SALVOZA, M FRANCO G | 1672 | §102§103Other | Non-Final OA | 98d overdue | Pending | Apr 14, 2023 |
| 18026336 | PROGRAMMING OF REGULATORY T CELLS BY EXTRACELLULAR VESICLES | CANELLA, KAREN A | 1643 | §103§112 | Final Rejection | — | Pending | Mar 14, 2023 |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | JUEDES, AMY E | 1644 | §112 | Final Rejection | 15d | Pending | Mar 14, 2023 |
| 18023536 | NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF | LUNDE, GRACE HENRY | 1641 | §103§112Other | Non-Final OA | 34d | Pending | Feb 27, 2023 |
| 18022708 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | CRAIG, KAILA ANGELIQUE | 1618 | §102§103§112 | Final Rejection | — | Pending | Feb 22, 2023 |
| 18042434 | LAMP DETECTION OF SARS-COV-2 IN SALIVA FOR THE RAPID DIAGNOSIS OF COVID-19 | SWITZER, JULIET CAROLINE | 1682 | §103 | Final Rejection | 23d overdue | Pending | Feb 21, 2023 |
| 18017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | MACFARLANE, STACEY NEE | 1675 | §103 | Final Rejection | 36d overdue | Pending | Jan 24, 2023 |
| 17998011 | METHODS FOR ORGANOIDS PRODUCTION | LEPAGE, JONATHAN EVERETT | 1796 | §102§103§112 | Final Rejection | — | Pending | Nov 04, 2022 |
| 17919178 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | REDDIG, PETER J | 1646 | §102§103 | Final Rejection | 8d overdue | Pending | Oct 14, 2022 |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | QIAN, CELINE X | 1637 | §103§112DP | Final Rejection | 217d overdue | Pending | Sep 14, 2022 |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 9d overdue | Pending | Sep 09, 2022 |
| 17870024 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY | PATTERSON, SARAH COOPER | 1675 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17789930 | METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS | BELYAVSKYI, MICHAIL A | 1644 | §103Other | Non-Final OA | 16d overdue | Pending | Jun 29, 2022 |
| 17843073 | ACCESS NEEDLE SYSTEMS AND METHODS | LI, JOHN DENNY | 3798 | §103 | Non-Final OA | 29d | Pending | Jun 17, 2022 |
| 17767398 | CANCER COMBINATION TREATMENTS USING ANTI-STAT3 NUCLEIC ACID CONJUGATES | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DPOther | Non-Final OA | — | Pending | Apr 07, 2022 |
| 17632869 | DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF | GURLEY, JAMI MICHELLE | 1647 | §102§103 | Final Rejection | — | Pending | Feb 04, 2022 |
| 17520402 | CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN | HINES, JANA A | 1645 | §103 | Final Rejection | 110d overdue | Pending | Nov 05, 2021 |
| 17184987 | Surgical Gauze | ARBLE, JESSICA R | 3781 | §102 | Non-Final OA | 26d | Pending | Feb 25, 2021 |
| 16968504 | PROMOTING AND PROTECTING FUNCTIONAL BETA CELL MASS BY SYNTAXIN 4 ENRICHMENT | CONNORS, ALEXANDRA F | 1634 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2020 |
| 16867803 | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13R-alpha-2 | REDDIG, PETER J | 1646 | DP | Non-Final OA | — | Pending | May 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial